Company news
Dermata Therapeutics, Inc. news in 2022
Dermata Therapeutics, Inc.'s news releases, calls and decks from 2022, newest first.
Dermata Announces Topline Results from DMT310 Phase 2 Clinical Trial for the Treatment of Moderate-to-Severe Rosacea
December 4, 2022
Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results
November 9, 2022
Dermata to Present at the H.C. Wainwright 24th Annual Global Investment Conference
September 5, 2022
Dermata to Participate in the Gilmartin Group Emerging Growth Company Showcase
August 23, 2022
Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial Results
August 14, 2022
Dermata Announces Final Patient Enrolled in a Phase 2 Trial of DMT310 for the Once-Weekly Treatment of Moderate-to-Severe Rosacea
June 12, 2022
Dermata to Present at the H.C. Wainwright Global Investment Conference
May 22, 2022
Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results
May 15, 2022
Dermata Therapeutics Announces Closing of $5.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
April 24, 2022
Dermata Therapeutics Announces $5.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
April 20, 2022
Dermata Therapeutics Provides Corporate Update and Reports Full Year 2021 Financial Results
March 27, 2022
Dermata Therapeutics to Participate in the 2022 Maxim Group Virtual Growth Conference
March 23, 2022
Dermata Appoints Life Science Executive Brittany Bradrick to Board of Directors
January 12, 2022
Dermata to Present at the H.C. Wainwright BioConnect Conference
January 4, 2022